ViroStatics

The mission of Virostatics is to leverage the team's rich history of success in scientific research and the development of intellectual properties to commercialize immunotherapeutic agents and novel drug combinations as innovative treatments to combat HIV/AIDS, viral infections and other global diseases.

The Company's focus is the development of virostatic drug combinations - rationally designed products that directly target disease-causing pathogens while also supporting the patient's immune system.
Virostatics' lead product, VS411, is currently in Phase II testing in a multinational trial as a treatment for HIV/AIDS.

With offices in Sassari, Italy and Princeton, New Jersey, USA, Virostatics continues the international approach to combating disease of our corporate parent, the Research Institute for Genetic and Human Therapy.

Latest News

October 1, 2008	The CEO, Dr. Franco Lori, speaking at the prestigious 2nd World Conference on Magic Bullets, (Ehrlich II) in Nürnberg, Germany on Saturday, October 4th 2008

May 28, 2008	Franco Lori on Sky Radio

more news >>>


	Contact us



	Sylva Petrocchi Chief Operational Officer Viale Umberto I, 46 - Sassari, Italy Phone: +39 3470723820 S.Petrocchi@Virostatics.com			Michael Stevens, PharmD Chief Development Officer 25 Fieldston Road - Princeton, NJ 08540 Phone: +1 609 987-2305 - Fax: +1 609 987-2305 M.Stevens@Virostatics.com